Posted by Michael Wonder on 18 Mar 2020
Coronavirus (COVID-19) update: FDA focuses on safety of regulated products while scaling back domestic inspections
18 March 2020 - Protecting the health and safety of our staff and their families is of paramount concern to the U.S. Food and Drug Administration.
As a nation we must do everything we can to help slow the spread of the virus and help flatten the curve of the COVID-19 pandemic. Now more than ever, the American people are depending on us. We must ensure our workforce remains healthy to carry out the FDA’s critical public health mission to keep Americans safe.
In keeping with the White House Coronavirus Task Force and cross-government guidance, this week we directed all eligible FDA employees to begin teleworking. While this does not apply to those carrying out non-portable activities, such as certain lab activities or the monitoring of imported products, we will continue to adjust our approach to a number of activities, including facility inspections for all FDA-regulated products such as food, animal feed, drugs, biological products, devices and tobacco.
